P Andy Futreal

83PUBLICATIONS
717CO-AUTHORS
Gene and molecular therapySolid tumoursMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (83)

|Jul 06, 2026
Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II.

|May 28, 2026
Pan-cancer spatial atlas of tertiary lymphoid structures.

|May 21, 2026
Drug Screening of Sarcoma Cells: Finding Shared Sensitivities.

|Apr 20, 2026
Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma.

|Nov 25, 2025
Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence.

Melinda Soeung, Xinmiao Yan, Ciro Zanca

|Aug 20, 2025
Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy.

Erez N Baruch, Frederico O Gleber-Netto, Priyadharsini Nagarajan

Pageof 14

Frequent Collaborators

33 joint publications

Jianhua Zhang

24 joint publications

Linghua Wang

18 joint publications

Alexander Lazar

16 joint publications

Jennifer Wargo